[Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0]
- PMID: 15332541
[Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0]
Abstract
We evaluated the reliability of CTC v 2.0 based on source documents and also studied the degree of inconsistency in toxicity grading. Five clinical research coordinators from the National Cancer Center Hospital independently reviewed source documents from 17 patients and graded toxicities in the following common adverse events: diarrhea, nausea, stomatitis/pharyngitis, vomiting, febrile neutropenia, infection, infection unknown source, and sensory neuropathy. If grading was already documented on the medical chart, it was masked so that the coordinator could perform the evaluation without information bias. After the completion of toxicity grading, the participating coordinators discussed each case, and a consensus was reached for final toxicity grading. The proportion of agreement for each toxicity criteria are as follows: diarrhea; 0.59 (95%CI 0.35-0.82), nausea; 0.47 (0.23-0.71), stomatitis/pharyngitis; 0.59 (0.35-0.82), vomiting; 0.71 (0.49-0.92), febrile neutropenia; 0.88 (0.73-1.04), infection; 0.82 (0.64-1.01), infection by unknown source; 0.82 (0.64-1.01), sensory neuropathy; 0.65 0.42-0.87). The cause of variability largely depended on the differences in individual clinical assessment, and misunderstanding of toxicity criteria by coordinators has been observed. Even in a single institution environment, variability exists in the toxicity assessment and grading. Good training and education on toxicity assessment using common criteria and development of translated manual, including the interpretation of criteria assessment, may help reduce variability.
Similar articles
-
[Analysis of adverse events of amrubicin hydrochloride for pretreated lung cancer patients].Gan To Kagaku Ryoho. 2007 Nov;34(11):1789-92. Gan To Kagaku Ryoho. 2007. PMID: 18030011 Japanese.
-
The grading of lymphedema in oncology clinical trials.Semin Radiat Oncol. 2003 Jul;13(3):214-25. doi: 10.1016/S1053-4296(03)00038-9. Semin Radiat Oncol. 2003. PMID: 12903011 Review.
-
[Toxicity of doxorubicin and cyclophosphamide (60 mg/600 mg/m2) in adjuvant chemotherapy for breast cancer].Gan To Kagaku Ryoho. 2005 Jun;32(6):809-13. Gan To Kagaku Ryoho. 2005. PMID: 15984521 Clinical Trial. Japanese.
-
Is there room for improvement in adverse event reporting in the era of targeted therapies?J Natl Cancer Inst. 2008 Feb 20;100(4):240-2. doi: 10.1093/jnci/djm324. Epub 2008 Feb 12. J Natl Cancer Inst. 2008. PMID: 18270340
-
[Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment].Nihon Rinsho. 2003 Jun;61(6):937-42. Nihon Rinsho. 2003. PMID: 12806939 Review. Japanese.
Cited by
-
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.Cochrane Database Syst Rev. 2016 Sep 27;9(9):CD009219. doi: 10.1002/14651858.CD009219.pub4. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2019 May 07;5:CD009219. doi: 10.1002/14651858.CD009219.pub5. PMID: 27669661 Free PMC article. Updated. Review.
-
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.Lancet. 2008 Mar 22;371(9617):1007-16. doi: 10.1016/S0140-6736(08)60455-9. Lancet. 2008. PMID: 18358928 Free PMC article. Clinical Trial.
-
Identification of biomarkers for radiation-induced acute intestinal symptoms (RIAISs) in cervical cancer patients by serum protein profiling.J Radiat Res. 2015 Jan;56(1):134-40. doi: 10.1093/jrr/rru081. Epub 2014 Sep 24. J Radiat Res. 2015. PMID: 25256248 Free PMC article. Clinical Trial.
-
Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19).Inflammopharmacology. 2022 Dec;30(6):1955-1976. doi: 10.1007/s10787-022-01061-4. Epub 2022 Sep 1. Inflammopharmacology. 2022. PMID: 36050507 Free PMC article. Review.
-
Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis.Malar J. 2009 Aug 23;8:203. doi: 10.1186/1475-2875-8-203. Malar J. 2009. PMID: 19698172 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources